Palliation of malignant ascites
- PMID: 30903617
- DOI: 10.1002/jso.25453
Palliation of malignant ascites
Abstract
Malignant ascites (MA) carries a poor prognosis. It can have a significant impact on quality of life (QOL), with increasing abdominal distention, pain, and dyspnea. Diuretics typically do not work well for MA. Paracentesis is effective in providing temporary symptom relief but requires frequent repeat procedures. Options for durable symptom management include indwelling catheters, peritoneal ports, peritoneovenous shunts, intraperitoneal (i.p.) catumaxomab, and hyperthermic i.p. chemotherapy. These interventions do not necessarily improve overall survival but may improve QOL.
Keywords: catumaxomab; hyperthermic intraperitoneal chemotherapy; paracentesis; peritoneal carcinomatosis.
© 2019 Wiley Periodicals, Inc.
Similar articles
-
Indwelling catheters for the management of malignant ascites.Support Care Cancer. 2000 Nov;8(6):493-9. doi: 10.1007/s005200000139. Support Care Cancer. 2000. PMID: 11094995
-
Current and future options in the treatment of malignant ascites in ovarian cancer.Anticancer Res. 2009 Aug;29(8):3353-9. Anticancer Res. 2009. PMID: 19661355
-
Palliation of malignant ascites.Gastroenterol Clin North Am. 2006 Mar;35(1):189-99, xi. doi: 10.1016/j.gtc.2005.12.006. Gastroenterol Clin North Am. 2006. PMID: 16530120 Review.
-
Narrative review of malignant ascites: epidemiology, pathophysiology, assessment, and treatment.Ann Palliat Med. 2024 Jul;13(4):842-857. doi: 10.21037/apm-23-554. Epub 2024 Apr 18. Ann Palliat Med. 2024. PMID: 38644553 Review.
-
[Pathogenesis and management of refractory malignant ascites].Bull Cancer. 2011 Jun;98(6):679-87. doi: 10.1684/bdc.2011.1373. Bull Cancer. 2011. PMID: 21636346 Review. French.
Cited by
-
Malignant Ascites in Ovarian Cancer: Cellular, Acellular, and Biophysical Determinants of Molecular Characteristics and Therapy Response.Cancers (Basel). 2021 Aug 26;13(17):4318. doi: 10.3390/cancers13174318. Cancers (Basel). 2021. PMID: 34503128 Free PMC article. Review.
-
B7H3-Directed Intraperitoneal Radioimmunotherapy With Radioiodinated Omburtamab for Desmoplastic Small Round Cell Tumor and Other Peritoneal Tumors: Results of a Phase I Study.J Clin Oncol. 2020 Dec 20;38(36):4283-4291. doi: 10.1200/JCO.20.01974. Epub 2020 Oct 29. J Clin Oncol. 2020. PMID: 33119478 Free PMC article. Clinical Trial.
-
Risk factors associated with complications of palliative drainage of ascites with tunneled peritoneal catheters.Therap Adv Gastroenterol. 2025 Jan 10;18:17562848241310183. doi: 10.1177/17562848241310183. eCollection 2025. Therap Adv Gastroenterol. 2025. PMID: 39802628 Free PMC article.
-
Localized Intra-Cavitary Therapy to Drive Systemic Anti-Tumor Immunity.Front Immunol. 2022 Feb 11;13:846235. doi: 10.3389/fimmu.2022.846235. eCollection 2022. Front Immunol. 2022. PMID: 35222439 Free PMC article.
-
Risk factors for early readmission to hospital in patients with malignancy-related ascites: a retrospective cohort study.Front Oncol. 2024 Oct 1;14:1409411. doi: 10.3389/fonc.2024.1409411. eCollection 2024. Front Oncol. 2024. PMID: 39411127 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
